Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1329-1338

  Dworakowska, D ^a,b   Wlodek, E ^a   Leontiou, C A ^a   Igreja, S ^a   Cakir, M ^a,c   Teng, M ^a   Prodromou, N ^a   Goth M I ^d   Grozinsky Glasberg, S ^a,e   Gueorguiev, M ^a   Kola, B ^a   Korbonits, M ^a   Grossman, A B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c SELCUK UNIVERSITY   (Turkey)

^d National Health Center   (Hungary)

^e RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; SERINE; THREONINE;

ACTH SECRETING ADENOMA; ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOBLOTTING; MALE; NEUROENDOCRINE TUMOR; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOMATOTROPHINOMA; TRANSSPHENOIDAL SURGERY; UPREGULATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL PROLIFERATION; CYCLIN D1; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAP KINASE KINASE KINASES; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PITUITARY NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RAF KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 68549139637     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0101     Document Type: Article

References (47)

1. Adjei AA & Hidalgo M 2005 Intracellular signal transduction pathway proteins as targets for cancer therapy. Journal of Clinical Oncology 23 5386-5403. (Pubitemid 46206992)
2. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB & Kondo Y 2007 Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Molecular Pharmacology 72 29-39. (Pubitemid 46998522)
3. Asa SL & Ezzat S 2002 The pathogenesis of pituitary tumours. Nature Reviews. Cancer 2 836-849.
4. Beckers A & Daly AF 2007 The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology 157 371-382. (Pubitemid 350018439)
5. Boikos SA & Stratakis CA 2007 Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Human Molecular Genetics 16 R80-R87.
6. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S & Melmed S 2008 p21(Cip1) restrains pituitary tumor growth. PNAS 105 17498-17503.
7. Cobb MH & Goldsmith EJ 1995 How MAP kinases are regulated. Journal of Biological Chemistry 270 14843-14846.
8. Cross DA, Alessi DR, Cohen P, Andjelkovich M & Hemmings BA 1995 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 785-789. (Pubitemid 26004411)
9. DePaoli-Roach AA 1984 Synergistic phosphorylation and activation of ATP-Mg-dependent phosphoprotein phosphatase by F A/GSK-3 and casein kinase II (PC0.7). Journal of Biological Chemistry 259 12144-12152. (Pubitemid 14019751)
10. Diehl JA, Cheng M, Roussel MF & Sherr CJ 1998 Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes and Development 12 3499-3511. (Pubitemid 28553242)
11. Dworakowska D & Grossman A 2009a Are neuroendocrine tumours a feature of tuberous sclerosis? Endocrine-Related Cancer16 45-58.
12. Dworakowska D & Grossman AB 2009b The pathophysiology of pituitary adenomas. Best Practice & Research. Clinical Endocrinology & Metabolism [in press].
13. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Cook RJ, Little NS, Robinson BG, Clifton-Bligh RJ & McDonald KL 2009 Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 94 1436-1442.
14. Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirjak S, Hanzely Z, Kola B et al. 2007 A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clinical Endocrinology 66 348-352. (Pubitemid 46239291)
15. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101 613-619. (Pubitemid 38970613)
16. Gazioglu NM, Erensoy N, Kadioglu P, Sayitoglu MA, Ersoy IH, Hatirnaz O, Kisacik B, Oz B, Sar M, Ozbek U et al. 2007 Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Medical Science Monitor 13 CR457-CR463. (Pubitemid 350017522)
17. Guan KL 1994 The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cellular Signalling 6 581-589.
18. Haystead TA, Dent P, Wu J, Haystead CM & Sturgill TW 1992 Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Letters 306 17-22.
19. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN & Farrell WE 1999 Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clinical Cancer Research 5 2133-2139.
20. Horvath A & Stratakis CA 2008 Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Reviews in Endocrine and Metabolic Disorders 9 1-11.
21. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S et al. 2006 Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European Journal of Endocrinology 155 371-379.
22. Inoki K, Li Y, Zhu T, Wu J & Guan KL 2002 TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biology 4 648-657. (Pubitemid 34993700)
23. Jones TH, Daniels M, James RA, Justice SK, McCorkle R, Price A, Kendall-Taylor P & Weetman AP 1994 Production of bioactive and immunoreactive interleukin-6 (IL-6) and expression of IL-6 messenger ribonucleic acid by human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 78 180-187. (Pubitemid 24026770)
24. Joneson T & Bar-Sagi D 1997 Ras effectors and their role in mitogenesis and oncogenesis. Journal of Molecular Medicine 75 587-593. (Pubitemid 27373601)
25. Jordan S, Lidhar K, Korbonits M, Lowe DG & Grossman AB 2000 Cyclin D and cyclin E expression in normal and adenomatous pituitary. European Journal of Endocrinology 143 R1-R6.
26. Karhu A & Aaltonen LA 2007 Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Human Molecular Genetics 16 R73-R79.
27. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J & Evan G 1997 Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385 544-548. (Pubitemid 27074674)
28. Lavoie JN, L'Allemain G, Brunet A, Muller R & Pouyssegur J 1996 Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. Journal of Biological Chemistry 271 20608-20616. (Pubitemid 26281839)
29. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J et al. 2008 The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 93 2390-2401. (Pubitemid 351831563)
30. Lewis TS, Shapiro PS & Ahn NG 1998 Signal transduction through MAP kinase cascades. Advances in Cancer Research 74 49-139. (Pubitemid 28193546)
31. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM et al. 1999 Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 84 3823-3830. (Pubitemid 30645248)
32. Lloyd RV, Jin L, Qian X & Kulig E 1997 Aberrant p27kip1 expression in endocrine and other tumors. American Journal of Pathology 150 401-407. (Pubitemid 27073769)
33. Lu C, Willingham MC, Furuya F & Cheng SY 2008 Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149 3339-3345. (Pubitemid 351919619)
34. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A et al. 2007 Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta 1773 1263-1284.
35. Melmed S 2008 Update in pituitary disease. Journal of Clinical Endocrinology and Metabolism 93 331-338.
36. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M et al. 2005 Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-Related Cancer 12 423-433. (Pubitemid 40896456)
37. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK & Renner U 2006 Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. Journal of Endocrinology 191 249-261. (Pubitemid 44756527)
38. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB & Rosen N 2009 (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. PNAS 106 4519-4524.
39. Roberts PJ & Der CJ 2007 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 3291-3310.
40. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A &Downward J 1997 Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89 457-467. (Pubitemid 27220890)
41. Rosenwald IB, Kaspar R, Rousseau D, Gehrke L, Leboulch P, Chen JJ, Schmidt EV, Sonenberg N & London IM 1995 Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. Journal of Biological Chemistry 270 21176-21180.
42. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K & Nevins JR 2000 Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes and Development 14 2501-2514. (Pubitemid 30761517)
43. Sonenberg N & Gingras AC 1998 The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Current Opinion in Cell Biology 10 268-275. (Pubitemid 28174770)
44. Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S & Marumo F 1999a Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney International 56 1258-1261. (Pubitemid 29451224)
45. Terada Y, Nakashima O, Inoshita S, Kuwahara M, Sasaki S & Marumo F 1999b Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Nephrology, Dialysis, Transplantation 14 45-47.
46. Tsagarakis S, Kontogeorgos G, Giannou P, Thalassinos N, Woolley J, Besser GM & Grossman A 1992 Interleukin-6, a growth promoting cytokine, is present in human pituitary adenomas: an immunocytochemical study. Clinical Endocrinology 37 163-167.
47. Volarevic S & Thomas G 2001 Role of S6 phosphorylation and S6 kinase in cell growth. Progress in Nucleic Acid Research and Molecular Biology 65 101-127.